- Home
- EQ vs BFRG Comparison
EQ vs BFRG Comparison
Compare EQ & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- BFRG
- Stock Information
- Founded
- EQ 2017
- BFRG 2017
- Country
- EQ United States
- BFRG United States
- Employees
- EQ N/A
- BFRG N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- BFRG Retail: Computer Software & Peripheral Equipment
- Sector
- EQ Health Care
- BFRG Technology
- Exchange
- EQ Nasdaq
- BFRG Nasdaq
- Market Cap
- EQ 24.8M
- BFRG 21.2M
- IPO Year
- EQ 2018
- BFRG 2023
- Fundamental
- Price
- EQ $0.59
- BFRG $2.01
- Analyst Decision
- EQ Buy
- BFRG
- Analyst Count
- EQ 2
- BFRG 0
- Target Price
- EQ $5.00
- BFRG N/A
- AVG Volume (30 Days)
- EQ 117.7K
- BFRG 201.5K
- Earning Date
- EQ 11-13-2024
- BFRG 11-08-2024
- Dividend Yield
- EQ N/A
- BFRG N/A
- EPS Growth
- EQ N/A
- BFRG N/A
- EPS
- EQ N/A
- BFRG N/A
- Revenue
- EQ $45,914,000.00
- BFRG N/A
- Revenue This Year
- EQ $4.76
- BFRG N/A
- Revenue Next Year
- EQ N/A
- BFRG N/A
- P/E Ratio
- EQ N/A
- BFRG N/A
- Revenue Growth
- EQ 7.70
- BFRG 550.00
- 52 Week Low
- EQ $0.56
- BFRG $1.43
- 52 Week High
- EQ $3.25
- BFRG $8.35
- Technical
- Relative Strength Index (RSI)
- EQ 33.48
- BFRG 41.32
- Support Level
- EQ $0.56
- BFRG $2.11
- Resistance Level
- EQ $0.67
- BFRG $2.77
- Average True Range (ATR)
- EQ 0.05
- BFRG 0.29
- MACD
- EQ -0.00
- BFRG -0.03
- Stochastic Oscillator
- EQ 15.79
- BFRG 7.32
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.